A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

INTRODUCTION:Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with...

Full description

Bibliographic Details
Main Authors: Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D Burt, Elaine McColl, Deborah D Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M Anstee, Christopher P Day
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5395178?pdf=render

Internet

http://europepmc.org/articles/PMC5395178?pdf=render

Similar Items